Navigation Links
STERIS Corporation Announces New $300 Million Share Repurchase Authorization

MENTOR, Ohio, March 14 /PRNewswire-FirstCall/ -- STERIS Corporation (NYSE: STE) today announced that its Board of Directors has authorized the purchase of up to $300 million in shares of STERIS common stock. The authorization represents approximately 20% of outstanding shares as of February 29, 2008. This share repurchase authorization replaces an existing authorization that had approximately $160 million remaining. Through March 13, 2008, the Company has repurchased approximately $162 million in common stock during fiscal year 2008, including $65 million to date in the fourth quarter ending March 31, 2008.

"We believe that our strong balance sheet and free cash flow level afford us the opportunity to use our capital structure to drive incremental returns to shareholders, while still being able to fund ongoing investments and growth in our business," said Walt Rosebrough, STERIS's president and chief executive officer. "During this fiscal year, we have been much more aggressive with share repurchases and this new authorization reflects our continued confidence in the Company's business and growth plans."

Under the new share repurchase authorization, the Company may purchase shares from time to time in open market purchases or privately negotiated transactions. This authorization has no time limit, and may be suspended or discontinued at any time. The Company may make all or part of the repurchases under Rule 10b5-1 plans. These plans may be entered into or terminated from time to time, and enable the Company to make repurchases on a more regular basis. The Company intends to finance the share repurchase program through a combination of available cash and debt.


The mission of STERIS Corporation is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. The Company's more than 5,000 dedicated employees around the world work together to supply a broad array of solutions by offering a combination of equipment, consumables and services to healthcare, pharmaceutical, industrial and government customers. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit

This news release may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," "confidence," and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, and changes in government regulations or the application or interpretation thereof. Other risk factors are described in the Company's Form 10-K and other securities filings. Many of these important factors are outside STERIS's control. No assurances can be provided as to any future financial results or continuation or level of share repurchase. Unless legally required, the Company does not undertake to update or revise any forward- looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products or applications, or the Company's business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings, regulations, certifications or other requirements or standards may delay or prevent new product introductions, affect the production and marketing of existing products, or otherwise affect Company performance, results, or value, (d) the potential of international unrest or effects of fluctuations in currencies, tax assessments or rates, raw material costs, benefit or retirement plan costs, or other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services, and (f) the possibility that anticipated cost savings may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, executive transition or other issues or risks associated with the matters described in this release, may adversely impact Company performance, results, or value.

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. STERIS Corporation Promotes Timothy L. Chapman to Group President of Healthcare
2. STERIS Corporation Announces Fiscal 2008 Third Quarter Results
3. STERIS Corporation Declares Regular Quarterly Dividend
4. STERIS Corporation Announces Date of Fiscal 2008 Third Quarter Earnings Release and Conference Call
5. STERIS Corporation Announces Fiscal 2008 Second Quarter Results
6. STERIS Corporation Announces Date of Fiscal 2008 Second Quarter Earnings Release and Conference Call
7. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
8. Dialysis Corporation of America Earnings Call Reminder
9. Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2007 Results
10. Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results
11. Providence Service Corporation Announces Intent to File a Common Stock Shelf Registration Statement
Post Your Comments:
(Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched from ... a convenient and comfortable way to protect them from bad weather, so I invented ... during cold or inclement weather. In doing so, it ensures that the user remains ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination ... in a way for homeless people to have a more dignified and comfortable ... initiative whereby they are repurposing plastic bags into sleeping mats for the homeless. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... focused on providing comprehensive solutions involving adult stem cell therapies to patients with ... deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 Kitov ... ) (TASE: KTOV), a biopharmaceutical company focused on the ... various clinical conditions, today announced the closing of its ... Shares ( ADSs ), each representing 20 ordinary shares ... 3,158,900 ADSs. The ADSs and warrants were issued in ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
Breaking Medicine Technology: